Guardant Health director sells 826 shares at $175

Guardant Health director Alex M. Azar II reported a small Rule 10b5-1 planned share sale, leaving him with 825 directly held shares.

Available on EDGAR 09/17/2026 - 05:10 PM EDT Accepted by SEC EDGAR 09/17/2026 - 05:09 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Guardant Health, Inc. (GH) director Alex M. Azar II reported selling 826 shares of common stock on September 16, 2026 in a sale described as occurring in the open market or a private transaction at a reported price of $175.00 per share. The transaction was reported as made under a Rule 10b5-1 trading plan, and following the sale he held 825 shares of Guardant Health common stock directly.

Insider Trade Summary 10b5-1

Net Seller: 826 shares

Net Sell 1 txn

Insider Azar Alex M II

Role Director

Sold 826 shs ($145K)

Share of Position Sold 50.0%

Type	Security	Shares	Price	Value
Sale	Common Stock	826	$175.00	$145K

Holdings After Transaction: Common Stock — 825 shares (Direct)

Holdings Before and After: Common Stock, 1,651 to 825 shares (Direct)

Other Insiders: 5 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Key Figures

Shares sold: 826 shares Sale price per share: $175.00 per share Shares held after transaction: 825 shares

3 metrics

Shares sold 826 shares Common stock sale reported for September 16, 2026

Sale price per share $175.00 per share Reported price for the 826 sold shares on September 16, 2026

Shares held after transaction 825 shares Directly held Guardant Health common stock following the sale

Key Terms

Rule 10b5-1 trading plan, open market, private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"The transaction was reported as made under a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open market market

"in a sale described as occurring in the open market or a private transaction"

An open market is a system where buying and selling of goods, services, or financial assets happen freely without restrictions or special controls. For investors, it means they can trade assets easily and quickly, which helps determine fair prices based on supply and demand. This environment encourages transparency and competition, making it easier to buy or sell with confidence.

private transaction market

"in a sale described as occurring in the open market or a private transaction"

A private transaction is the sale or transfer of securities, assets, or ownership stakes carried out directly between a small number of parties rather than on a public exchange. For investors it matters because these deals are less visible and often less liquid than public trades, so pricing can be harder to verify, the investment can be harder to sell quickly, and buyers or sellers may gain strategic advantages not available in open markets — like negotiated terms similar to a private garage sale versus a crowded marketplace.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GH director Alex M. Azar II report?

Alex M. Azar II reported a sale of 826 Guardant Health (GH) common shares on September 16, 2026, in a transaction described as occurring in the open market or a private transaction at a reported price of $175.00 per share, leaving him with 825 directly held shares.

Was the recent GH insider sale by Alex M. Azar II under a Rule 10b5-1 plan?

Yes. The reported sale of 826 GH shares by director Alex M. Azar II on September 16, 2026 was reported as made under a Rule 10b5-1 trading plan, indicating it was made pursuant to a pre-established trading arrangement.

How many GH shares did Alex M. Azar II sell and at what price?

Alex M. Azar II sold 826 shares of Guardant Health common stock on September 16, 2026 at a reported price of $175.00 per share in a sale described as occurring in the open market or a private transaction.

How many GH shares does Alex M. Azar II hold after the reported sale?

After the September 16, 2026 transaction, Alex M. Azar II held 825 shares of Guardant Health common stock directly, as reported in the insider ownership information that accompanied the sale.

What type of security did Alex M. Azar II trade in the GH Form 4 filing?

The Form 4 filing reports a transaction in Guardant Health common stock. On September 16, 2026, Alex M. Azar II sold 826 common shares at a reported price of $175.00 per share, with 825 shares remaining held directly afterward.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Azar Alex M II

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2026		S		826	D	$175	825	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Alex M. Azar II	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)